RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sio Gene Therapies Stock

Sio Gene Therapies Employees 2024

Sio Gene Therapies Employees

38

Ticker

SIOX

ISIN

US8293991043

WKN

A2QHKW

In 2024, Sio Gene Therapies employed 38 people, a 0% change from the 38 number of employees in the previous year.

Sio Gene Therapies Aktienanalyse

What does Sio Gene Therapies do?

Sio Gene Therapies Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. The company was founded in 2000 by a team of scientists specializing in the research of gene therapies for the treatment of rare diseases. Sio Gene Therapies' history began with the goal of providing an alternative treatment method for patients with rare diseases. The company focuses on the discovery and development of gene therapies based on the use of vectors to deliver genes into defective cells. The company has focused on diseases such as Huntington's chorea, Parkinson's disease, and rare hereditary diseases. Sio Gene Therapies' business model is designed to develop and market gene therapy as a novel therapy for rare diseases. The company pursues an innovative research program that aims to discover rare diseases and identify genetic mutations associated with these diseases. Sio Gene Therapies collaborates with leading scientists and research institutions to develop innovative approaches to the treatment of rare genetic diseases. Sio Gene Therapies has several divisions, including a research facility, a development department, and a sales department. Each of these departments plays a crucial role in the development of gene therapies for rare diseases. The research department identifies new target genes for the development of gene therapies, the development department develops and tests vectors for gene therapy, and the sales department works closely with physicians and health authorities to market and make gene therapy available. Sio Gene Therapies has developed a range of products based on gene therapy. This includes Axovant, a gene therapy for the treatment of Parkinson's disease that aims to deliver genes into defective cells. The drug is currently in the clinical testing stage. Peroxysome biogenesis disorder (PBD) is a rare hereditary disease caused by a dysfunction of peroxisomes. The company has already completed initial clinical studies with its product AXO-AAV-CLN6, a gene therapy approach for PBD. The results of these studies are promising, and the company is currently in Phase III of clinical studies. Sio Gene Therapies has achieved several milestones in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy for the treatment of rare degenerative retinal diseases. In August 2020, the company initiated a Phase III study for the treatment of PBD with AXO-AAV-CLN6. Overall, Sio Gene Therapies has established itself as a successful company in the gene therapy industry and has specialized in the development of gene therapies for rare genetic diseases. The company has made significant progress in the development of gene therapies in recent years and has also received important approvals from the FDA. Through ongoing research and development of new products, the company intends to contribute to the treatment and cure of rare genetic diseases in the future. Sio Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Sio Gene Therapies's Employee Base

Sio Gene Therapies's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Sio Gene Therapies's operational capacity and future potential.

Year-to-Year Comparison

Assessing Sio Gene Therapies's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Sio Gene Therapies's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Sio Gene Therapies’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Sio Gene Therapies stock

How many employees does Sio Gene Therapies have this year?

Sio Gene Therapies has 38 undefined employees this year.

How many employees did Sio Gene Therapies have compared to the previous year?

Compared to the previous year, Sio Gene Therapies had 0% more employees.

What impact did the number of employees have on the company Sio Gene Therapies?

The number of employees has a direct impact on the efficiency and productivity of Sio Gene Therapies. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Sio Gene Therapies?

The number of employees can also have an impact on investors of Sio Gene Therapies, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Sio Gene Therapies affect the company?

An increase in equity of Sio Gene Therapies can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Sio Gene Therapies's equity affect the company?

A reduction in equity of Sio Gene Therapies can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Sio Gene Therapies?

Some factors that can influence the equity of Sio Gene Therapies include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Sio Gene Therapies so important for investors?

The equity of Sio Gene Therapies is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Sio Gene Therapies influence the company?

The number of employees at Sio Gene Therapies can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Sio Gene Therapies evolved in recent years?

In recent years, the number of employees at Sio Gene Therapies has changed by 0.

How many employees does Sio Gene Therapies currently have?

Sio Gene Therapies currently has 38 undefined employees.

Why is the number of employees important for investors of Sio Gene Therapies?

The number of employees is important for investors of Sio Gene Therapies as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Sio Gene Therapies take to change the number of employees?

To change the number of employees, Sio Gene Therapies can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Sio Gene Therapies pay?

Over the past 12 months, Sio Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sio Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Sio Gene Therapies?

The current dividend yield of Sio Gene Therapies is .

When does Sio Gene Therapies pay dividends?

Sio Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sio Gene Therapies?

Sio Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Sio Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sio Gene Therapies located?

Sio Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sio Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sio Gene Therapies from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Sio Gene Therapies pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Sio Gene Therapies in the year 2023?

In the year 2023, Sio Gene Therapies distributed 0 USD as dividends.

In which currency does Sio Gene Therapies pay out the dividend?

The dividends of Sio Gene Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sio Gene Therapies

Our stock analysis for Sio Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sio Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.